A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Inclusion Criteria: * Age 18-70 years old； * ECOG performance scale 0-1； * Life expectancy of more than 3 months； * Histologically or cytologic confirmed melanoma； * Temozolomide has not been previously treated； * Patients who have failed at least one systemic treatment regimen： including but not limited to patients receiving immunotherapeutics such as PD-1 monoclonal antibodies, PDL-1 monoclonal antibodies, ipilimumab, C-kit inhibitors, Braf inhibitors, and molecular targeted drugs. * For results of blood routine test and biochemical tests： Hgb\>100g/L, ANC\>2.0×109/L, PLT\>100×109/L, Serum Total bilirubin ≤ 1.5 X UNL, ALT and AST ≤ 2.5 x upper normal limit (UNL), and ≤ 5 x UNL（Hematogenous metastases）, Serum Creatine ≤ 1.5 x UNL； * Informed consent； * Willingness and ability to comply with scheduled visits. Exclusion Criteria: * Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg)； * With ≥grade 2 coronary heart disease, arrhythmia (including QTc interval prolongation male ≥450 ms, women ≥470 ms)； * Imaging studies have shown that the tumor has been infringing on an important perivascular or when the researcher determines that the patient's tumor has a high risk of fatal hemorrhage during treatment； * Abnormal Coagulation (INR\>1.5, PT\>UNL+4 seconds), with tendency of bleed or receiving the therapy of thrombolysis or anticoagulation.； * Urine protein ≥++ or confirmed \>1.0 g by the 24h quantity； * Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures； * A history of psychotropic substance abuse and can not be abstinent or mental disorders ； * There are serious concomitant diseases that endanger patient safety or affect the patient in completing the study； * Patients participating in other clinical trials simultaneously； * Other situations that the researchers considered unsuitable for this study； * Confirmed brain metastasis.